BIOA
BioAge Labs, Inc. NASDAQ Listed Sep 26, 2024$18.46
After hrs
$18.46
+0.00%
Mkt Cap $664.2M
52w Low $3.67
72.7% of range
52w High $24.00
50d MA $18.58
200d MA $12.01
P/E (TTM)
-7.5x
EV/EBITDA
-3.1x
P/B
2.2x
Debt/Equity
0.0x
ROE
-29.6%
P/FCF
-5.8x
RSI (14)
—
ATR (14)
—
Beta
1.83
50d MA
$18.58
200d MA
$12.01
Avg Volume
541.1K
About
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for th…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | BMO | -0.83 | -0.72 | +13.3% | 16.11 | +1.1% | +1.9% | +1.9% | +0.9% | +0.2% | -1.7% | — |
| Nov 6, 2025 | BMO | -0.67 | -0.56 | +16.4% | 7.47 | -2.7% | -2.8% | -2.8% | +0.3% | +4.8% | +7.2% | — |
| Aug 6, 2025 | BMO | -0.56 | -0.60 | -7.1% | 4.33 | +1.8% | -0.2% | -0.2% | +0.0% | +0.2% | +3.5% | — |
| May 6, 2025 | BMO | -0.52 | -0.36 | +30.8% | 3.95 | +0.8% | +2.8% | +2.8% | +4.1% | +2.3% | +3.0% | — |
| Mar 20, 2025 | BMO | -0.58 | -1.97 | -239.7% | 4.38 | -3.2% | +2.5% | +2.5% | +3.7% | -2.3% | -8.9% | — |
| Nov 7, 2024 | BMO | -0.72 | -6.70 | -830.6% | 20.62 | +1.1% | +7.6% | +7.6% | +9.9% | -3.0% | -2.2% | — |
| Sep 26, 2024 | BMO | — | -1.80 | — | 18.31 | +5.4% | +14.7% | +14.7% | +13.6% | +10.6% | +7.8% | — |
| Mar 31, 2024 | BMO | — | -1.74 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | BMO | — | -2.81 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | BMO | — | -1.96 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10 | Citigroup | Maintains | Buy → Buy | — | $19.73 | $20.37 | +3.2% | +6.3% | +1.7% | +0.8% | -5.1% | +9.2% |
| Feb 18 | Jefferies | Upgrade | Hold → Buy | — | $19.63 | $21.40 | +9.0% | -0.2% | +2.6% | +4.5% | +8.8% | +9.8% |
| Dec 8 | Morgan Stanley | Upgrade | Underweight → Equal Weight | — | $11.61 | $11.35 | -2.2% | +1.9% | +3.9% | +9.2% | +9.8% | +10.9% |
| Oct 29 | Citigroup | Maintains | Buy → Buy | — | $7.89 | $8.00 | +1.4% | -2.7% | -2.0% | -4.1% | -6.0% | -5.3% |
| Oct 22 | Citigroup | Upgrade | Neutral → Buy | — | $5.30 | $5.69 | +7.4% | +14.2% | +50.0% | +43.4% | +44.0% | +48.9% |
| Mar 24 | Citigroup | Maintains | Neutral → Neutral | — | $4.49 | $4.37 | -2.7% | +1.1% | -4.7% | -11.1% | -13.6% | -14.9% |
| Dec 9 | Citigroup | Downgrade | Buy → Neutral | — | $20.09 | $5.65 | -71.9% | -76.9% | -77.8% | -76.1% | -77.2% | -78.7% |
| Dec 9 | Jefferies | Downgrade | Buy → Hold | — | $20.09 | $5.65 | -71.9% | -76.9% | -77.8% | -76.1% | -77.2% | -78.7% |
Recent Filings
Data updated apr 24, 2026 9:40pm
· Source: massive.com